JP2015519334A - 抗血小板薬のプロドラッグ - Google Patents

抗血小板薬のプロドラッグ Download PDF

Info

Publication number
JP2015519334A
JP2015519334A JP2015510901A JP2015510901A JP2015519334A JP 2015519334 A JP2015519334 A JP 2015519334A JP 2015510901 A JP2015510901 A JP 2015510901A JP 2015510901 A JP2015510901 A JP 2015510901A JP 2015519334 A JP2015519334 A JP 2015519334A
Authority
JP
Japan
Prior art keywords
formula
independently
compound
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519334A5 (https=
Inventor
カンデュラ，マヘシュ
Original Assignee
セリックスビオ プライヴェート リミテッド
セリックスビオ プライヴェート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/053673 external-priority patent/WO2013024376A1/en
Application filed by セリックスビオ プライヴェート リミテッド, セリックスビオ プライヴェート リミテッド filed Critical セリックスビオ プライヴェート リミテッド
Publication of JP2015519334A publication Critical patent/JP2015519334A/ja
Publication of JP2015519334A5 publication Critical patent/JP2015519334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015510901A 2012-05-07 2013-03-24 抗血小板薬のプロドラッグ Pending JP2015519334A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1781CH2012 2012-05-07
IN1781/CHE/2012 2012-05-07
IBPCT/IB2012/053673 2012-07-19
PCT/IB2012/053673 WO2013024376A1 (en) 2011-08-16 2012-07-19 Compositions and methods for the treatment of atherothrombosis
PCT/IB2013/052328 WO2013168024A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Publications (2)

Publication Number Publication Date
JP2015519334A true JP2015519334A (ja) 2015-07-09
JP2015519334A5 JP2015519334A5 (https=) 2015-08-27

Family

ID=54193687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510901A Pending JP2015519334A (ja) 2012-05-07 2013-03-24 抗血小板薬のプロドラッグ

Country Status (8)

Country Link
EP (1) EP2847197A4 (https=)
JP (1) JP2015519334A (https=)
CN (1) CN104379589A (https=)
AU (1) AU2013257745A1 (https=)
CA (1) CA2873094A1 (https=)
SG (1) SG11201407307YA (https=)
WO (1) WO2013168024A1 (https=)
ZA (1) ZA201408064B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527309A (ja) * 2012-07-03 2015-09-17 セリックスビオ プライヴェート リミテッド 中等度から重度の疼痛の治療のための組成物及び方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119033782B (zh) * 2020-07-29 2025-04-25 上海柯君医药科技有限公司 抗血小板药物和其用途
CN114507157B (zh) * 2020-11-17 2023-03-24 沧州维智达美制药有限公司 一种利用氯乙腈制备溴乙腈的方法
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510621A (ja) * 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス，エルエルシー． アミノ酸プロドラッグ
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
JP2015508956A (ja) * 2012-01-27 2015-03-23 インターデイジタル パテント ホールディングス インコーポレイテッド マルチキャリアベースおよび／または疑似照合ネットワークにおいてｅｐｄｃｃｈを提供するためのシステムおよび／または方法
JP2015510306A (ja) * 2012-01-06 2015-04-02 クゥアルコム・インコーポレイテッドＱｕａｌｃｏｍｍ Ｉｎｃｏｒｐｏｒａｔｅｄ マルチスクリーンサービスを用いたワイヤレスディスプレイ
JP2015519333A (ja) * 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
JP2015520748A (ja) * 2012-05-08 2015-07-23 セリックスビオ プライヴェート リミテッド 炭酸脱水酵素活性の抑制のための組成物及び方法
JP2015521174A (ja) * 2012-05-08 2015-07-27 セリックスビオ プライヴェート リミテッド 糖尿病の治療のための組成物および方法
JP2015526385A (ja) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド てんかんの治療のための組成物及び方法
JP2015527309A (ja) * 2012-07-03 2015-09-17 セリックスビオ プライヴェート リミテッド 中等度から重度の疼痛の治療のための組成物及び方法
JP2015533114A (ja) * 2012-05-08 2015-11-19 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
EP1889835A4 (en) * 2005-05-27 2010-04-28 Daiichi Sankyo Co Ltd CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
KR100990949B1 (ko) * 2008-06-09 2010-10-29 엔자이텍 주식회사 클로피도그렐 및 그의 유도체의 제조방법
CN102336767A (zh) * 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510621A (ja) * 2003-07-29 2007-04-26 シグニチャー アールアンドディー ホールディングス，エルエルシー． アミノ酸プロドラッグ
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
JP2015510306A (ja) * 2012-01-06 2015-04-02 クゥアルコム・インコーポレイテッドＱｕａｌｃｏｍｍ Ｉｎｃｏｒｐｏｒａｔｅｄ マルチスクリーンサービスを用いたワイヤレスディスプレイ
JP2015508956A (ja) * 2012-01-27 2015-03-23 インターデイジタル パテント ホールディングス インコーポレイテッド マルチキャリアベースおよび／または疑似照合ネットワークにおいてｅｐｄｃｃｈを提供するためのシステムおよび／または方法
JP2015519333A (ja) * 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
JP2015520748A (ja) * 2012-05-08 2015-07-23 セリックスビオ プライヴェート リミテッド 炭酸脱水酵素活性の抑制のための組成物及び方法
JP2015521174A (ja) * 2012-05-08 2015-07-27 セリックスビオ プライヴェート リミテッド 糖尿病の治療のための組成物および方法
JP2015526385A (ja) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド てんかんの治療のための組成物及び方法
JP2015533114A (ja) * 2012-05-08 2015-11-19 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物及び方法
JP2015527309A (ja) * 2012-07-03 2015-09-17 セリックスビオ プライヴェート リミテッド 中等度から重度の疼痛の治療のための組成物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527309A (ja) * 2012-07-03 2015-09-17 セリックスビオ プライヴェート リミテッド 中等度から重度の疼痛の治療のための組成物及び方法

Also Published As

Publication number Publication date
SG11201407307YA (en) 2014-12-30
AU2013257745A1 (en) 2014-11-27
WO2013168024A1 (en) 2013-11-14
EP2847197A1 (en) 2015-03-18
ZA201408064B (en) 2016-04-28
CA2873094A1 (en) 2013-11-14
CN104379589A (zh) 2015-02-25
EP2847197A4 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
WO2013168022A1 (en) Compositions and methods for treating atherothrombosis
EP3004049B1 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2013168014A1 (en) Compositions and methods for the treatment of familial amyloid polyneuropathy
JP2015518855A (ja) 粘膜炎の治療のための組成物および方法
JP2015520748A (ja) 炭酸脱水酵素活性の抑制のための組成物及び方法
WO2014087307A2 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
JP2015519334A (ja) 抗血小板薬のプロドラッグ
JP2015519334A5 (https=)
JP2015518854A (ja) 多発性硬化症の治療のための組成物および方法
JP2015519333A5 (https=)
JP2015527309A (ja) 中等度から重度の疼痛の治療のための組成物及び方法
US9403826B2 (en) Compositions and methods for the treatment of inflammatory disorders
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
RU2751770C2 (ru) Композиции и способы лечения синдрома раздраженного кишечника
JP2015521174A (ja) 糖尿病の治療のための組成物および方法
JP2015526385A (ja) てんかんの治療のための組成物及び方法
JP2015533114A (ja) 神経疾患の治療のための組成物及び方法
WO2014118649A2 (en) Compositions and methods for the treatment of cardiovascular diseases
US9309233B2 (en) Compositions and methods for the treatment of blood clotting disorders
US20150087697A1 (en) Compositions and methods for the treatment of muscle pain
WO2014195810A2 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
US9175008B1 (en) Prodrugs of anti-platelet agents
JP2016510306A (ja) 高血糖の治療のための組成物及び方法
WO2014147541A2 (en) Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases
WO2014041445A2 (en) Compositions and methods for the treatment of hypertension and management of diabetic kidney disease

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170530